In the Sweet Spot · · Zoetis (ZTS) · Healthcare

Zoetis: Quality Animal-Health Franchise Trading Near a 52-Week Low, With a Same-Day FDA Nod

Zoetis screens with 94.2 quality and an 18.4% PAR near the top of our sweet spot, but a tough stretch of earnings calls and a fresh FDA emergency authorization make today worth a closer look.

Zoetis (ZTS) was Manifest Investing's In the Sweet Spot daily stock pick for August 14, 2026. At the time of the pick, Zoetis carried a quality percentile of 94 and a projected annual return (PAR) of 18.4% against a MIPAR of 8.7%, placing it inside the sweet spot of 13.7% to 18.7%.

Key metrics at the time of the pick

Quality percentile
94
Projected annual return (PAR)
18.4%
MIPAR (median PAR of coverage)
8.7%
PROVE
12.8%
Core score (of 300)
283
Financial strength (of 100)
91
EPS stability (of 100)
97.2
Sales growth forecast
5.3%
P/E ratio
17.5
Price at pick
$75.41
52-week low
$71.45
52-week high
$160.48
Above 52-week low
5.5%
Below 52-week high
53.0%
Dividend yield
2.6%
Projected yield
1.7%
In the sweet spot
Yes
Triple play
No

Why Zoetis, why today

Zoetis (ZTS) sits at $75.41, just 5.5% above its 52-week low of $71.45 and roughly 53% below its 52-week high of $160.48. That combination of a beaten-down price and a still-excellent underlying business is exactly the kind of tension we like to dig into in this feature.

The immediate news hook: on August 13, the FDA granted Zoetis’s Simparica Trio an emergency use authorization for treating New World screwworm infestations in dogs and puppies, per Businesswire and Reuters coverage. It’s a small, specific development, but it lands the same week the stock touched a fresh 52-week low following a price-target cut from Piper Sandler (per Defenseworld.net), so the stock has had two very different kinds of news in a matter of days.

What our methodology shows

Zoetis carries a quality percentile of 94.2, meaning it ranks in the top 6% of all the stocks we cover on financial strength, EPS stability, and relative sales growth and profitability. Underneath that, financial strength is a strong 91.4 (out of 100) and EPS stability is 97.2 (out of 100), reflecting a long history of consistent earnings. Add those two figures to the 94.2 quality percentile and you get a core score of 283 out of a possible 300, comfortably above the 225 threshold we associate with core-holding candidates.

On return expectations, Zoetis’s projected annual return (PAR) is 18.4%, which sits near the top of our sweet spot, the band running from MIPAR (currently 8.7%) plus 5 to plus 10 percentage points, or 13.7% to 18.7%. A PAR this high after a large price decline is consistent with the methodology: as the price falls and the underlying growth and profitability assumptions hold, projected return rises. The stock’s growth forecast is a modest 5.3%, and it trades at a P/E of 17.5, with a current dividend yield of 2.65% versus a projected yield of 1.7%.

The honest complication

We’d be doing readers a disservice if we didn’t flag what’s driving that depressed price. Our AI review of Zoetis’s recent earnings calls, covering Q4 2025 through Q2 2026, found a business under real pressure. Management cut full-year guidance twice in six months as U.S. Companion Animal sales turned negative and the key Dermatology franchise saw a new competitor enter the market. That same review also credited two real bright spots: Livestock and Companion Animal Diagnostics have both posted consistent double-digit growth across the same stretch, providing ballast while the U.S. pet-care business works through a rough patch. Leadership changes announced alongside the Q2 report, including a new CFO/COO starting August 17, add a layer of execution risk to watch during the recovery.

Zoetis’s next earnings date is November 3, 2026, roughly three months out, giving investors a window to watch whether the gross-to-net pricing investments management has deployed start to show up in stabilized market share before then.

The takeaway for research

This is a name where a high quality score and a sweet-spot PAR coexist with a genuinely challenged near-term operating picture. That’s not a contradiction in our methodology, it’s the methodology doing its job: pricing in the uncertainty via a lower stock price and, mechanically, a higher projected return. Whether the animal-health franchise’s competitive and macro pressures prove temporary or more structural is exactly the kind of question worth studying further, not a conclusion we’re drawing for you.

This is educational research content, not a recommendation to buy or sell. Always consider your own goals, risk tolerance, and further due diligence.

Sources

Zoetis has also been the In the Sweet Spot pick on: July 9, 2026.

About In the Sweet Spot

Manifest Investing's daily stock pick: one high-quality company whose projected annual return (PAR) sits in the sweet spot above the market median (MIPAR). Each pick pairs Manifest Investing's quality percentile with its projected annual return (PAR); the sweet spot runs from MIPAR + 5 to MIPAR + 10 percentage points. Browse every pick in the archive.

In the Sweet Spot is educational and is not investment advice or a recommendation to buy or sell any security. Figures reflect Manifest Investing's methodology as of the pick date.